Advertisement
A live web cast and recording of the presentation will be available for 30days following the presentation on AtriCure's Investor Relations page atwww.atricure.com.
Advertisement
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and leader in developing,manufacturing and selling innovative cardiac surgical ablation systemsdesigned to create precise lesions, or scars, in cardiac, or heart, tissues.Medical journals have described the adoption by leading cardiothoracicsurgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatmentalternative during open-heart surgical procedures to create lesions in cardiactissue to block the abnormal electrical impulses that cause atrialfibrillation, or AF, a rapid, irregular quivering of the upper chambers of theheart. Additionally, leading cardiothoracic surgeons have described theAtriCure Isolator(R) clamps as a promising treatment alternative for patientswho may be candidates for sole-therapy minimally invasive procedures. AFaffects more than 2.5 million Americans and predisposes them to a five-foldincreased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system,including the new Isolator Synergy(TM) ablation clamps, for the ablation, ordestruction, of soft tissues in general and cardiac related surgicalprocedures, but to date has not cleared or approved the system for thetreatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Penfor the ablation of cardiac tissue and for temporary pacing, sensing,stimulating and recording during the evaluation of cardiac arrhythmias, butthe multifunctional bipolar Pen has not been approved for the treatment of AF.AtriCure's left atrial appendage clip system has not been approved forcommercial use. It is currently being used in clinical evaluations in Europe.Contact: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 [email protected]
SOURCE AtriCure, Inc.
